BSX ($43.26) Bounces Off a New Low as WATCHMAN and EP Shrink — Base Builds Between $40 and $47

Boston Scientific (NYSE: BSX) traded at $43.26 late in Wednesday’s session, down $1.80 or 4.0% from Tuesday’s close of $45.06, after a third-quarter report that cut full-year guidance for the third time in 2026. The stock fell 13% to $39.40 before the regular session opened, dropped as much as 12% in early trading and opened near $42.02, before buyers absorbed most of the selling. At the low, BSX traded below its prior 52-week bottom of $41.39.

The numbers explain the panic. Third-quarter net sales rose just 1.5% to $5.138 billion on a reported, operational and organic basis, below the company’s own guidance of 3% to 5%. Adjusted EPS fell 3% to $0.73, below the $0.80 to $0.82 range set in July and the $0.75 consensus. GAAP EPS dropped to $0.40 from $0.51. Management cut full-year adjusted EPS guidance to $3.16 to $3.18 from $3.28 to $3.32, against a $3.23 consensus, and lowered 2026 sales growth to about 4.25%, from 5.5% to 6.5% in July and 10.5% to 11.5% in February.

The fourth-quarter outlook was worse. Boston Scientific expects net sales to decline 1% to 3% in the fourth quarter, with adjusted EPS of $0.77 to $0.79, against the $0.83 analysts expected. Chief executive Mike Mahoney said the company will be challenged to grow sales and adjusted EPS in 2027 excluding the pending Penumbra acquisition.

The thesis for the stock is that the cyberattack is the excuse but not the cause. An August 25 cyberattack shut every plant and distribution center for eight days and cut third-quarter sales by roughly $150 million, about 300 basis points of growth, and EPS by $0.07. But WATCHMAN sales fell 6% and electrophysiology fell 5% in the quarter, the two franchises that drove the company’s growth for three years. The business was slowing before the attack, and management now expects WATCHMAN to hit its worst point in 2027.

The rebound off $39.40 says the market sees value at these levels. At $43.26, BSX trades at 13.6 times the midpoint of its new 2026 EPS guidance, close to its lowest forward multiple in five years. The forecast is a base between $40 and $47 while the market waits for January’s 2027 guidance and the Penumbra close. A reclaim of $46 to $47 would signal a bottom. A daily close below $39.40 would open the high $30s.

Q3: $5.138 Billion in Sales, Up 1.5%, Adjusted EPS of $0.73

The third-quarter results showed a company that has stopped growing. Net sales of $5.138 billion rose $73 million from $5.065 billion a year earlier, a gain of 1.5% on every basis. For a company that grew 15.9% on a reported basis in the fourth quarter of 2025, that is a collapse in momentum within three quarters.

The segment split shows where the slowdown sits. Cardiovascular sales rose 1.9% to $3.406 billion, from $3.343 billion, despite substantial declines in electrophysiology and WATCHMAN. MedSurg sales rose 0.6% on a reported basis and 0.7% organically to $1.733 billion, from $1.722 billion. Within MedSurg, Neuromodulation grew 13.0% to $331 million, Endoscopy fell 0.6% to $741 million and Urology fell 3.1% to $661 million.

Profitability fell faster than sales. GAAP net income attributable to common stockholders dropped 23% to $582 million, or $0.40 a share, from $755 million, or $0.51. Adjusted net income fell to $1.063 billion from $1.124 billion. Adjusted EPS of $0.73 compared with $0.75 a year earlier, a 3% decline.

Reported operating income fell 21% to $828 million from $1.048 billion, as cost of products sold jumped $187 million to $1.710 billion. The GAAP results included $81 million of litigation-related charges, $63 million of net restructuring charges, $39 million of intangible asset impairments and $234 million of amortization. Interest expense rose to $100 million from $87 million.

The nine-month numbers mask the slowdown. For the first nine months of 2026, net sales rose 6.7% to $15.784 billion, GAAP EPS rose to $1.92 from $1.49, and adjusted EPS rose to $2.39 from $2.26. The year started strongly in the first quarter, slowed sharply in the second and stalled in the third.

Share count is shrinking. Diluted shares fell to 1,452.0 million from 1,495.5 million a year earlier, a decline of 2.9%, after a $2 billion accelerated share repurchase earlier in the year that bought roughly 40 million shares. Fewer shares supported EPS, but not enough to offset the operating decline.

Three Guidance Cuts in One Year: 11% Growth in February, 4.25% Now

Boston Scientific has cut its 2026 outlook every quarter this year. In February, the company guided to 10.5% to 11.5% sales growth. In April, it cut to 7% to 8.5%. In July, it cut again to 5.5% to 6.5% and set adjusted EPS at $3.28 to $3.32, below a $3.36 consensus. On Wednesday it cut a third time, to about 4.25% reported and 3.75% organic growth, with adjusted EPS of $3.16 to $3.18.

The sequence has destroyed the stock’s growth premium. Each cut in this sequence came with a sharp decline in the shares. On February 4, BSX fell more than 17%, its largest one-day percentage drop since July 2000, after a cautious 2026 outlook and disappointing key product sales. It fell to a 26-month low of $60.46 on April 21, and closed at $56.81 on May 19 after another leg down. By late October, it traded near $45.

The fourth-quarter guidance implies sales will shrink. A decline of 1% to 3% would mean fourth-quarter net sales between $5.13 billion and $5.23 billion, against $5.286 billion in the fourth quarter of 2025. That would be Boston Scientific’s first year-over-year sales decline since the pandemic.

The EPS guidance includes a further cyber hit. Fourth-quarter adjusted EPS of $0.77 to $0.79 incorporates an estimated $0.04 to $0.05 impact from residual inventory adjustments tied to the cyber incident. Without that hit, fourth-quarter adjusted EPS would be roughly $0.82 to $0.83, close to the $0.83 consensus.

The full-year math confirms the reset. Nine-month adjusted EPS of $2.39 plus fourth-quarter guidance of $0.77 to $0.79 produces $3.16 to $3.18 for 2026. That would be up from $3.06 in 2025, but well below the $3.28 to $3.32 range the market had already discounted in July.

Credibility is now the issue. Three cuts in nine months, each larger than the market expected, have eroded investors’ confidence in management’s forecasts. Boston Scientific will not give 2027 guidance until January, which leaves investors with three months of uncertainty about how deep the downturn will run.

An Eight-Day Shutdown Cost $150 Million and 300 Basis Points of Growth

The cyberattack was severe. Boston Scientific identified the attack on August 25 and first reported it publicly on August 26. It shut every plant and distribution center for eight days, temporarily halting ordering, manufacturing and shipping. In September, the company warned it was unlikely to meet its third-quarter and full-year targets, without giving specific figures.

The quantified impact landed on Wednesday. Management estimated the incident reduced third-quarter sales growth by approximately 300 basis points and adjusted EPS by $0.07. That equals roughly $150 million in lost revenue in the quarter. Without the attack, organic growth would have been roughly 4.5%, inside the original 3% to 5% guidance range.

The impact concentrated internationally. Management said the cyber incident contributed roughly half of the electrophysiology miss, primarily in international markets. EMEA still grew 6.1% operationally, Latin America and Canada grew 10.5%, while APAC fell 1.1%. The US, Boston Scientific’s largest market at $3.309 billion, grew just 0.5%.

The attack carries into the fourth quarter. Residual inventory adjustments will cost $0.04 to $0.05 of adjusted EPS, as the company works through stock that was disrupted during the shutdown. Hospitals that delayed procedures during the outage may have rescheduled them, or they may have switched to competitors’ devices.

That question is the central uncertainty. Deferred procedures that return in the fourth quarter would help the company recover. Procedures that went to Medtronic, Abbott or Johnson & Johnson devices during the outage may not come back, because hospitals that train staff on a competitor’s system often stay with it. In the electrophysiology market, where Boston Scientific was already losing share, the outage may have accelerated that loss.

Mahoney described the response in positive terms, praising global teams for working with urgency and resilience to restore operations. But the attack exposed operational fragility in a company that ships single-use devices to hospitals worldwide. Rebuilding customer trust and supply chain resilience will add costs to 2027 margins, which management has already flagged as under pressure from investment in supply chain and quality systems.

WATCHMAN Fell 6% as Standalone Procedures Dropped High Teens

WATCHMAN, Boston Scientific’s left atrial appendage closure device, has gone from growth engine to drag. Sales declined 6% in the third quarter, falling 7% in the US and growing 4% internationally. WATCHMAN grew nearly 30% in 2025 to $1.96 billion. In the first quarter of 2026, it grew 19.2% to $506 million. In the second quarter, it grew 4.3% to $507 million. In the third, it shrank.

The procedure mix explains the decline. Within the US, concomitant procedures, in which WATCHMAN is implanted during an ablation procedure, grew roughly 35% year over year. Standalone procedures, in which WATCHMAN is the only procedure, declined in the high teens versus the third quarter of 2025. Standalone procedures were the core of the franchise, and their decline has outweighed the growth in concomitant cases.

The shift began in February. Boston Scientific experienced declining WATCHMAN volume for the first time beginning that month. Mahoney described a dramatic shift over six months, with declines in standalone procedures partially offset by growth in concomitant use. Clinical trial results earlier this year added pressure: mixed outcomes for WATCHMAN FLX and EKOS drove BSX to a two-year low at the time.

Management expects the worst is still ahead. Mahoney said the WATCHMAN business would be at its maximum decline in 2027 and return to a healthier position in 2028. The company assumes WATCHMAN market dynamics will not improve from current conditions next year. The overall WATCHMAN market is roughly $2 billion, and a new competitive launch in left atrial appendage closure is expected in 2027.

The pipeline is the path back. In the third quarter, Boston Scientific began enrolling the Elite AF clinical trial for the next-generation WATCHMAN Elite device, targeting patients with non-valvular atrial fibrillation who are eligible for anticoagulation but seek a non-drug alternative. If successful, the trial would expand the eligible population and could restore standalone growth, but results are years away.

For the stock, WATCHMAN is the swing factor in 2027. A franchise that generated nearly $2 billion of sales with high margins is now shrinking, and every point of decline in WATCHMAN hits gross margin harder than a decline in a lower-margin business.

Electrophysiology Fell 5%, With US Sales Down 8%

Electrophysiology has followed WATCHMAN into decline. EP sales fell 5% in the third quarter, with a decline of 8% in the US and growth of 2% internationally. On a reported basis, the company’s slides showed a 5.7% decline. Management estimated the cyber incident accounted for roughly half the miss, primarily internationally.

The fall from growth is stark. EP was Boston Scientific’s fastest-growing business for three years, driven by its FARAPULSE pulsed field ablation platform. The EP market has transformed over the past few years, led by FARAPULSE, and the franchise saw triple-digit growth at its peak. In the first quarter of 2026, EP sales rose nearly 24% to $905 million. In the second quarter, growth slowed to just over 9% at $916 million. In the third, sales shrank.

The decline reflects share loss. Boston Scientific has lost more market share than expected in pulsed field ablation as competitors launched their own systems. The EP segment faced significant share erosion in the US in the third quarter, and management expects second-half 2026 share-loss rates to persist into 2027.

The company is fighting back with launches. Boston Scientific continues to expand its OPAL mapping system footprint and drive utilization of mapping systems with its FARAWAVE and FARAPOINT catheters. Management highlighted three launches for 2027: an intracardiac echocardiography platform, a full year of FARAPULSE Ultra, and, pending approval, a FLEX catheter. Management said the FLEX approval has slipped by roughly one quarter due to issues with regulators, not clinical data.

Mapping integration is the strategic battleground. Competitors increasingly offer pulsed field ablation catheters integrated with their own mapping systems, which lets hospitals use a single vendor’s platform for the full procedure. Boston Scientific’s OPAL push aims to close that gap, but it is playing catch-up in a market it created.

The EP decline also hits WATCHMAN. Concomitant WATCHMAN procedures are performed alongside ablation, so share loss in EP reduces the number of procedures where Boston Scientific can sell both devices together. The two franchises reinforce each other on the way up and drag each other on the way down.

Neuromodulation Grew 13% While China Hit Urology and Endoscopy

The MedSurg segment showed one bright spot and two weak ones. Neuromodulation sales rose 13.0% to $331 million, the fastest growth of any business line in the quarter. Endoscopy fell 0.6% to $741 million and Urology fell 3.1% to $661 million.

China is the common problem. Urology’s decline reflected commercial turnover and pricing pressure in China. Endoscopy’s decline came primarily from volume-based procurement in China, a government purchasing program that forces steep price cuts in exchange for volume, plus shipping delays from the cyber incident. Management flagged escalating China pricing as a pressure on 2027 gross margins.

The regional numbers show China’s drag. APAC sales fell 0.6% on a reported basis and 1.1% operationally to $797 million. EMEA grew 4.4% reported and 6.1% operationally to $829 million. Latin America and Canada grew 16.0% reported and 10.5% operationally to $203 million. The US grew 0.5% to $3.309 billion.

New products are coming in MedSurg. Boston Scientific received FDA 510(k) clearance for two technologies in its StoneSmart kidney stone ecosystem: the Navigator Flex Ureteral Access Sheath Set, designed to use suction to remove stone debris, and the LithoVue Elite single-use digital flexible ureteroscope with temperature sensing. It also received FDA clearance for an expanded size range of the SEISMIQ intravascular lithotripsy peripheral catheter for calcified arteries above and below the knee.

Reimbursement milestones support future growth. The American Medical Association assigned Category I CPT codes for renal denervation devices, including Boston Scientific’s investigational TIVUS system, and implantable tibial nerve stimulation devices, including the eCoin system, effective January 2028. Those codes allow hospitals to bill for the procedures, which is a precondition for broad adoption.

Boston Scientific also entered a strategic collaboration with Heartflow to advance AI-powered, CT-guided planning for percutaneous coronary intervention. The deal integrates Heartflow’s PCI Navigator tool with Boston Scientific’s AVVIGO+ guidance system. These are long-dated growth options that do not offset the near-term decline in the two largest franchises.

Gross Margin Fell to 66.7% From 69.9% and Faces More Pressure in 2027

Margins are falling with growth. GAAP gross profit fell to $3.428 billion from $3.542 billion, a gross margin of 66.7% against 69.9% a year earlier, a decline of 320 basis points. On an adjusted basis, gross profit was $3.493 billion, a margin of 68.0% against 71.0%, a 300-basis-point decline.

The mix shift drives the margin decline. WATCHMAN and EP carry some of the highest margins in Boston Scientific’s portfolio. When those businesses shrink while lower-margin lines hold steady, the overall margin falls even if total sales are flat. The cyber incident added costs from idle plants and disrupted shipments.

Adjusted operating margin also compressed. Adjusted operating income fell to $1.364 billion from $1.419 billion, an adjusted operating margin of 26.5% against 28.0% a year earlier. Adjusted operating expenses fell to $2.128 billion from $2.175 billion, which shows management cutting costs, but not fast enough to offset the gross margin decline.

Management warned that 2027 gross margins face significant pressure from EP and WATCHMAN mix, escalating China pricing and continued investment in supply chain and quality systems. That is a multi-year margin headwind layered on top of a sales slowdown.

Restructuring is the offset. Boston Scientific is executing a restructuring program designed to reduce gross annual pre-tax expenses by approximately $500 million as the benefits are realized. Restructuring charges of $63 million in the third quarter, against an $8 million credit a year earlier, reflect that program. Savings of $500 million would add roughly 2.3 percentage points to operating margin on a $21 billion revenue base, enough to offset part of the gross margin pressure.

The margin trajectory matters for valuation. A company growing low single digits with shrinking margins earns a far lower multiple than one growing double digits with expanding margins, which is exactly the shift BSX has gone through in 2026.

“Challenged to Grow Sales and EPS in 2027” Excluding Penumbra

The most damaging comment on the call concerned next year. Mahoney said the company will be challenged to grow sales and adjusted EPS in 2027 excluding the pending Penumbra acquisition. Management framed 2026 and 2027 as a down cycle led by EP and WATCHMAN, after several years of exceptional growth, with restructuring and launches intended to restore growth in 2028.

That framing resets expectations for two years. Even before Wednesday’s cut, the market expected only about 5% revenue growth in 2027. Mahoney’s comment implies flat to declining organic sales and flat to declining adjusted EPS, a far weaker outlook than consensus had assumed.

The drivers are specific. Management expects WATCHMAN market dynamics to stay at current levels, EP share-loss rates to persist from the second half of 2026, and China pricing to add pressure. WATCHMAN faces weak standalone procedures, decelerating concomitant growth and a new competitive launch in 2027. Gross margin will take a hit from mix and China.

The offset is product launches. Management pointed to the intracardiac echocardiography platform launch, a full year of FARAPULSE Ultra, and the pending FLEX approval in EP. Restructuring savings of $500 million provide a cost cushion. But management’s message was clear that those offsets will not be enough to restore growth in 2027.

Formal guidance arrives in January. Boston Scientific will not give 2027 guidance until its fourth-quarter report. That leaves three months in which the market has to price a company whose management has said it may not grow, without a specific range to anchor expectations.

The long-term view is more constructive. Mahoney said he remains confident in the company’s long-term strategy, fueled by talent, a differentiated portfolio and a strong pipeline. Management said its actions will position the company to stabilize in 2027 and then drive growth again. Investors who buy at $43.26 are betting on that 2028 recovery, and the stock’s rebound from $39.40 shows that some are willing to make that bet.

The $14.5 Billion Penumbra Deal Now Closes in Early 2027

The Penumbra acquisition is Boston Scientific’s main growth lever for 2027. Boston Scientific agreed to acquire Penumbra (NYSE: PEN), a maker of thrombectomy devices used to remove blood clots, in a transaction valued around $14.5 billion and financed with a combination of cash and stock. The deal was announced alongside the fourth-quarter 2025 results.

The timeline has slipped. Mahoney said the regulatory process has taken longer than expected, and that the company now anticipates an early first-quarter close in 2027. He said Boston Scientific remains very confident in closing the transaction. The delay means Penumbra’s revenue will not contribute to 2026 results and will contribute to only part of the first quarter of 2027.

The deal reshapes the growth profile. Penumbra operates in vascular thrombectomy and stroke intervention, markets growing faster than Boston Scientific’s current core. Adding Penumbra’s revenue would lift Boston Scientific’s reported growth in 2027 and 2028, even if the organic business stalls. That is why Mahoney’s 2027 warning explicitly excluded Penumbra.

The financing carries costs. A cash-and-stock deal of $14.5 billion adds debt and dilutes existing shareholders. Interest expense already rose to $100 million in the third quarter from $87 million a year earlier, and the Penumbra financing will push it higher. The stock component dilutes earnings per share, which matters when organic EPS growth is expected to stall.

Integration adds execution risk. Boston Scientific has a long record of acquisitions, but it is integrating Penumbra while managing a cyber recovery, a restructuring program, three product launches in EP and a WATCHMAN downturn. Management bandwidth is stretched.

The strategic logic is defensible. With EP and WATCHMAN in a down cycle, Boston Scientific needs a new growth engine, and Penumbra provides one in a market adjacent to its cardiovascular franchise. If the deal closes on schedule and Penumbra’s growth holds, it could offset a meaningful share of the 2027 decline in the legacy franchises. If the close slips further, 2027 will look even weaker.

Medtronic, Abbott and J&J Are Taking Share in Pulsed Field Ablation

Boston Scientific’s problems are partly the result of competitors catching up. In pulsed field ablation, FARAPULSE had a head start of several years, which drove triple-digit EP growth. Medtronic (NYSE: MDT), Abbott (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) have since launched competing systems, and the US share loss that drove an 8% decline in Boston Scientific’s US EP sales reflects their progress.

Integrated mapping is the competitive edge. Competitors offer pulsed field catheters that work with their own established mapping and navigation platforms, which lets hospitals standardize on one vendor’s ecosystem. Boston Scientific’s push to expand its OPAL mapping footprint is a response to that dynamic.

In left atrial appendage closure, competition is coming. A new competitive launch is expected in 2027, which will challenge WATCHMAN’s dominant position in a roughly $2 billion market. Abbott already markets a competing closure device, and additional entrants would put further pressure on pricing and share.

Large-cap medtech peers have had a mixed October. Johnson & Johnson’s stock fell after its third-quarter report on October 14 despite raised guidance, showing that investors are demanding more than beats in the sector. Boston Scientific’s 52% year-to-date decline makes it the worst performer among large US medical device makers.

The competitive picture is not permanent. Boston Scientific remains a scale player with deep relationships across cardiology, a broad product portfolio and a strong pipeline. Its FARAPULSE installed base gives it a foothold in thousands of hospitals, and next-generation products like FARAPULSE Ultra and the pending FLEX catheter are designed to regain share.

The risk is that share loss compounds. Hospitals that move to a competitor’s integrated system during Boston Scientific’s cyber outage or product gaps may not return. Each point of share lost in a market growing double digits is revenue that takes years to win back. The 2027 guidance in January will reveal how much share management expects to recover.

Valuation: 13.6 Times 2026 EPS After a 59% Fall From the High

The stock has been repriced from growth to value. At $43.26, BSX trades at 13.6 times the $3.17 midpoint of its new 2026 adjusted EPS guidance. With 1.45 billion shares outstanding, its market capitalization stands at roughly $62.7 billion, down from approximately $136 billion after the fourth-quarter 2025 report in February.

The drawdown is severe. The stock’s 52-week range ran from $41.39 to $105.65 before Wednesday’s session, and Wednesday’s premarket low of $39.40 set a new bottom. At $43.26, BSX is down 59% from the $105.65 high, down 52% to 53% year to date, and down 55% over 12 months. The stock briefly matched its lowest forward price-to-earnings ratio of the past five years on Wednesday.

That multiple prices a stagnant company. A forward P/E of 13.6 times is consistent with flat or slowly declining earnings, which matches management’s 2027 warning. It is a steep discount to the 30-plus times earnings the stock commanded in 2025, when organic growth ran in the mid-teens.

The value case rests on three pillars. First, the cyber hit is temporary, and its $0.07 to $0.12 of 2026 EPS impact will not recur in 2027. Second, the $500 million restructuring program provides a cost cushion. Third, Penumbra adds a growth engine from early 2027. If adjusted EPS holds near $3.17 in 2027 and grows again in 2028, a return to 16 times earnings would put the stock near $51.

The bear case prices a deeper decline. If 2027 adjusted EPS falls 5% to around $3.00 on WATCHMAN and EP declines, China pricing and Penumbra dilution, and the multiple stays at 13 times, the stock would trade near $39, close to Wednesday’s low.

Options traders had priced an earnings reaction of plus or minus 8.36%, or $3.53, ahead of the report. The intraday low of 12% exceeded that range, but the late-session decline of 4.0% came in well inside it, which shows the market absorbed the bad news faster than expected.

The Technical Map: $39.40 Below, $45.06 and $47 Above

BSX’s chart shows a reversal off a new low. Wednesday’s premarket low of $39.40 broke the prior 52-week bottom of $41.39, but the stock recovered to trade at $43.26, reclaiming the old low and closing the session well off its worst levels. That intraday pattern, a sharp break followed by a strong recovery, often marks capitulation when it occurs on heavy volume after a prolonged decline.

Immediate support sits at $42.02, Wednesday’s open, and $41.39, the prior 52-week low. A close back below $41.39 would signal the reversal has failed. Below that, $39.40, Wednesday’s low, is the critical floor. A daily close below $39.40 would open the high $30s, with $36 to $37 as the next zone.

Resistance starts at $45.06, Tuesday’s close and the full gap fill. Above that, $46.01, the October 22 close, and $46.55, the October 23 high, form the next band. The $47 level marks the top of the late-October range. A close above $47 would signal the post-earnings drop has been fully absorbed and the stock has formed a base.

Further up, $50.37 marks the August 21 close, and $52 to $52.56 marks the August 19 range, when the stock rallied on the first round of cyber-related news. The May 19 close at $56.81 and the April low near $60.46 represent the levels the stock would need to reclaim to show the downtrend has reversed.

The distances frame the setup. From $43.26, the downside to $39.40 is $3.86, or 8.9%. The upside to $45.06 is $1.80, or 4.2%, and to $47 is $3.74, or 8.6%. Near-term risk is balanced, with the capitulation low beneath and the gap fill and late-October range above.

The year-long trend remains down. The stock has made a series of lower highs since February, with each guidance cut producing a new low. A base requires the stock to hold above $39.40 through January’s 2027 guidance, which is the next major catalyst.

Boston Scientific Stock Forecast: $40–$47 Base, $51 on a Credible 2027, $37 on a Break

The forecast for BSX rests on whether $39.40 marked capitulation or a waypoint. The company cut 2026 guidance for the third time, guided to a fourth-quarter sales decline of 1% to 3%, warned that it may not grow sales or EPS in 2027 excluding Penumbra, and reported 6% and 5% declines in WATCHMAN and EP, its two growth franchises. The stock fell as much as 13% before recovering to $43.26, 13.6 times the midpoint of 2026 EPS guidance.

The base case is a range between $40 and $47 through January’s 2027 guidance. The cyber recovery proceeds, fourth-quarter results land within the $0.77 to $0.79 EPS range, Penumbra closes in early 2027 as planned, and investors wait for the 2027 numbers. The stock trades as a value name around 13 to 14 times earnings, with the $39.40 low as support and the $45 to $47 gap zone as resistance.

The bullish case targets $47, then $51. It requires January’s 2027 guidance to show flat-to-slightly-higher adjusted EPS including Penumbra, evidence that fourth-quarter procedures deferred by the cyberattack returned rather than going to competitors, early traction for FARAPULSE Ultra and the ICE platform, and FDA approval for the FLEX catheter. A credible restructuring path to $500 million in savings would support a multiple expansion toward 16 times.

The bearish case targets $37. It requires a fourth-quarter miss, January guidance pointing to a 2027 EPS decline beyond 5%, accelerating US EP share loss, a further delay in the Penumbra close, and escalating China pricing. A daily close below $39.40 would confirm the reversal has failed and open the high $30s.

The verdict is cautiously constructive on a 12-month view and neutral in the near term. The stock has priced a stagnant company at 13.6 times earnings, the cyber impact is temporary, Penumbra adds growth from 2027, and the intraday reversal from $39.40 suggests capitulation. But management’s own words point to a 2027 without organic growth, WATCHMAN at its trough next year and margins under pressure, which limits upside until January. BSX at $43.26 is a speculative buy on dips toward $40 to $41 with a stop below $39.40, a reduce near $47 unless January guidance surprises, and a close above $47 opens $51.

That's TradingNEWS